TCT 2022 | FAME-3 Trial: post PCI FFR And IVUS in Patients with Three-Vessel Disease

We are well aware of the benefits of Fractional Flow Reserve (FFR) to assess coronary artery stenosis. FFR after PCI (post-PCI FFR) has been shown to have prognostic value; however, few studies have included patients with complex three-vessel disease. The impact of intravascular ultrasound (IVUS) or optical computer tomography (OCT) in this field has been even more overlooked.  

TCT 2022

The aim of this multicenter randomized study was to assess the prognostic value of post PCI FFR and intravascular imaging in patients undergoing PCI for three vessel disease in the FAME 3. 

Primary end point was target vessel failure (TVF), a combination of cardiovascular death, treated vessel MI (TVMI) and target vessel revascularization (TVR) at 1 year. 

Of 1500 patients included in the FAME 3 trial, 757 were randomized to FFR guided PCI. Of these, 61% were measured with FFR after PCI, and 15% had three-vessel disease. The artery most frequently assessed was the anterior descending, followed by the right coronary. Mean FFR value was 0.89. 9.1% had post PCI FFR 0.8 or lower. Post PCI FFR in the anterior descending artery was 0.87, while mean post PCI FFR in any other artery was 0.92.

Post PCI FFR value was a significant predictor of TVF at 1 year (HR=0.67 [95% CI: 0.48-0.93]. There was a significant and progressive reduction of TVF according to post PCI FFR values. 

Read also: TCT 2022 | BYPASS CTCA.

As regard IVUS imaging, there were no differences in cardiovascular death rate, AMI or the need for repeat revascularization vs. patients with no IVUS imaging. 

Conclusion

Post PCI FFR was an independent predictor of TVF in patients with three-vessel disease. The use of IVUS had no effect on the assessed outcomes. 

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Prognostic Value of Measuring Fractional Flow Reserve after Percutaneous Coronary Intervention in Patients with Complex Coronary Artery Disease: Insights from the FAME 3 Trial.

Reference: Zsolt Piroth, MD, PhD et al.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroSMR Registry: Edge-to-Edge Mitral Treatment with 5-Year Outcomes

Cardiomyopathies and left atrial enlargement can lead to secondary mitral regurgitation (SMR). This condition is associated with ventricular dysfunction, causing heart failure, hospitalization, and...

TricValve Transcatheter Bicaval Valve System for Severe Tricuspid Insufficiency: Events at One Year

TricValve is the first bicaval valve system to obtain CE-Mark approval. This device heterotopic device eliminates tricuspid insufficiency reflux into the venous system, reducing...

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...